MXCT MaxCyte, Inc.
MaxCyte, Inc. (MXCT) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -10.7% since its last earnings release on November 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MaxCyte, Inc.
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies.
Sector
Healthcare
Industry
Medical Instruments/Supply
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.